Edwards Lifesciences Corp
NYSE: EW · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
Edwards Lifesciences Corp (EW) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.25B | $1.35B | $1.40B | $1.62B | $1.77B | $1.98B | $2.22B | $2.72B | $3.52B | $4.06B | $4.51B | $5.70B | $5.32B | $6.49B | $7.24B | $8.50B | $8.29B | $9.36B | $13.06B | $13.70B |
| Cash & equivalents | $182.80M | $141.80M | $218.70M | $334.10M | $396.10M | $171.20M | $310.90M | $420.40M | $653.80M | $718.40M | $930.10M | $818.30M | $714.10M | $1.18B | $1.18B | $862.80M | $769.00M | $1.13B | $3.05B | $2.94B |
| Current assets | $531.60M | $581.70M | $691.90M | $889.20M | $1.03B | $1.17B | $1.29B | $1.73B | $2.29B | $2.05B | $2.24B | $2.53B | $2.29B | $2.98B | $3.09B | $3.18B | $3.10B | $4.04B | $6.29B | $6.74B |
| Total liabilities | $497.40M | $510.10M | $521.40M | $457.60M | $459.00M | $642.60M | $742.20M | $1.17B | $1.33B | $1.56B | $1.89B | $2.70B | $2.18B | $2.34B | $2.66B | $2.67B | $2.49B | $2.64B | $2.99B | $3.36B |
| Current liabilities | $226.20M | $375.40M | $258.50M | $290.50M | $337.80M | $335.20M | $347.40M | $345.60M | $434.40M | $476.20M | $532.50M | $1.40B | $876.60M | $902.40M | $893.90M | $1.03B | $1.02B | $1.20B | $1.51B | $1.81B |
| Long-term debt | $235.90M | $61.70M | $175.50M | $90.30M | $0.00 | $150.40M | $189.30M | $593.10M | $598.10M | $596.90M | $822.30M | $438.40M | $593.80M | $594.40M | $595.00M | $595.70M | $596.30M | $597.00M | $597.70M | $598.30M |
| Shareholder equity | $749.40M | $835.00M | $878.80M | $1.16B | $1.31B | $1.34B | $1.48B | $1.56B | $2.19B | $2.50B | $2.62B | $2.99B | $3.14B | $4.15B | $4.57B | $5.84B | $5.81B | $6.65B | $10.00B | $10.34B |
| Retained earnings | $433.90M | $548.60M | $676.90M | $906.00M | $1.12B | $1.36B | $1.65B | $2.05B | $2.84B | $3.34B | $3.91B | $2.00B | $2.69B | $3.74B | $4.57B | $6.07B | $7.59B | $8.99B | $13.17B | $14.24B |
| Accounts receivable | $127.10M | $145.30M | $204.70M | $272.10M | $302.50M | $320.70M | $347.50M | $328.00M | $325.00M | $344.10M | $414.60M | $479.30M | $537.30M | $599.10M | $602.80M | $664.90M | $699.10M | $828.10M | $727.40M | $912.10M |
| Inventory | $142.10M | $152.60M | $151.80M | $165.90M | $203.60M | $261.30M | $281.00M | $308.90M | $296.80M | $339.90M | $396.60M | $554.90M | $607.00M | $640.90M | $802.30M | $726.70M | $875.50M | $903.50M | $1.09B | $1.13B |
| Goodwill | $337.70M | $350.30M | $315.70M | $315.20M | $315.20M | $349.80M | $384.70M | $385.40M | $376.00M | $628.30M | $626.10M | $1.13B | $1.11B | $1.17B | $1.17B | $1.17B | $1.16B | $1.15B | $1.78B | $1.77B |
Frequently asked questions
What is Edwards Lifesciences Corp's revenue?
Edwards Lifesciences Corp's trailing twelve-month revenue is $6.30B, and consensus projects about $9.71B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is EW?
In its most recent fiscal year, EW ran a gross margin of 78.13%, an operating margin of 26.97%, and a net margin of 17.69%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does EW generate?
EW produced $1.33B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is EW's balance sheet healthy?
EW holds $2.94B in cash and equivalents against $598.30M in long-term debt, on $10.34B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.